التفاصيل البيبلوغرافية
العنوان:
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
المؤلفون:
Kaplanov, K. D. , ÖZCAN, MEHMET ALİ , Udovitsa, D. P. , Ilyin, N. , Alekseev, S. M. , Fadjari, H. , Arumugan, V. , Chakrabarti, P. , Kirushnakumar, K. S. , Attili, A. V. S. Suresh , Dantas da Cunha Junior, A. , Schmidt Filho, J. , Franke, F. A. , Sampaio Tavares, R. , Pinto Simoes, B. , Miguel, C. E. , Meton, F. , Boquimpani, C. , Schaffel, R. , Cigno, E. L. , Basso, A. C. , Jarchum, G. , Heller, V. B. , Bullorsky, E. , Furque, M. L. , Jones, L. , Bassa, F. , Osmanov, D. S. , Burdaeva, O. N. , Melnichenko, V. Y. , Uy, N. A. , Keat, C. Teng , Rosales, J. D. , Galvez, K. , Lazaretti, N. , Debiasi, M. , Santi, P. Xavier , de Mattos, E. R. , Luiz da Silva, R. , Rodrigues de Oliveira, J. S. , Pereira, J. , Salvino de Araujo, A. , Fogliatto, L. , Beguelin, G. Z. , Saslavsky, M. M. , Munoz, M. , Avila, G. I. , Moiseevich, M. G. , Viktorovich, P. A. , Tiangco, B. J. , Molina Barrios, G. R. , Martinez-Lapus, F. G. P. , Villegas, E. M. , Raman, R. , Gin, G. Gin , Bermudez, C. , Ciliao Munhoz, E. , Garcia, J. J. , De Stefano, G. , Caffaro, J. , Syafei, S. , da Silva Araujo, S. Shusterschitz , Kowalyszyn, R. D. , Jasuja, S. , Bhurani, D. , Radhakrishnan, V. , Salvatierra, A. , Mukhopadhyay, A. , Bhattacharyya, S. , Bhatt, N. , Perez Diaz, Luis , Paravisini, Alexandra , Fogliatto, Laura , Nodehi, Sayyed Reza Safaee , Patel, Moosa , Volodicheva, Elena Mikhailovna , Lipatov, Oleg Nikolaevich , Guan, Toh See , Querol, John , Flores, David Hugo , Dasappa, Lokanatha , Beniwal, Surender Kumar , Bar, Daniel Oscar , Delamain, Marcia Torresan , Gonzalez, Derlis E. , Candelaria, Myrna , Florez, A. , Michiels, S. , Leao, D. , Loggetto, S. R. , Szpak, W. , Lifirenko, I. D. , Ponomarev, R. S. , Lysenko, I. B. , Vladimirov, V.
المصدر:
Leukemialymphoma . 60(14)
سنة النشر:
2019
مصطلحات موضوعية:
Adult , Male , Cancer Research , medicine.medical_specialty , Adolescent , CHOP , Gastroenterology , law.invention , 03 medical and health sciences , Young Adult , 0302 clinical medicine , Randomized controlled trial , Double-Blind Method , immune system diseases , law , hemic and lymphatic diseases , Internal medicine , Antineoplastic Combined Chemotherapy Protocols , medicine , Humans , Adverse effect , Biosimilar Pharmaceuticals , Cyclophosphamide , Aged , business.industry , Immunogenicity , Hematology , Middle Aged , medicine.disease , Prognosis , Lymphoma , Survival Rate , Oncology , Doxorubicin , Vincristine , 030220 oncology & carcinogenesis , Pharmacodynamics , Prednisone , Rituximab , Female , Lymphoma, Large B-Cell, Diffuse , business , Diffuse large B-cell lymphoma , 030215 immunology , medicine.drug , Follow-Up Studies
الوصف:
This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients
تدمد:
1029-2403
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914865134a0fa1b9718405e5d0316a01Test https://pubmed.ncbi.nlm.nih.gov/31432721Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....914865134a0fa1b9718405e5d0316a01
قاعدة البيانات:
OpenAIRE
